|
||||
 NCCN Receives $4 Million In Oncology Research Funding From GlaxoSmithKlineJuly 29, 2010
The National Comprehensive Cancer Network (NCCN) has been awarded two individual $2 million grants from GlaxoSmithKline (GSK) to support clinical studies of ofatumumab (Arzerra®, GlaxoSmithKline) in the treatment of hematologic malignancies and pazopanib (Votrient®, GlaxoSmithKline) in the treatment of solid tumors...
read full article
You may also be interested in these articles:
|
||||
|
|
||||
|
home | featured services | faq | health news | contact
This information is not designed to replace a physician's independent judgment about the appropriateness or risks of a procedure for a given patient. Always consult your doctor about your medical conditions. FirstAndHealth.com does not provide medical advice, diagnosis or treatment. All materials were gathered from publicly available 3rd party resources and are NOT approved or reviewed by medical doctors. |
